Search Results 281-290 of 17435 for Mmol

1. A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity - Mayo Clinic

   Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L without transfusion or erythropoietin dependency (within 7 days of assessment);; Serum creatinine < 1.5 X institutional ...

2. Bortezomib, Rituximab, and Dexamethasone with or without Temsirolimus in Treating Patients with Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma - Mayo Clinic

   Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 x institutional upper limit of normal (ULN), within 28 days prior to ...

3. Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL or 5.6 mmol/L. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN unless participant is receiving ...

4. A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 - Mayo Clinic

   Mean 24-hour urinary oxalate excretion from the first 2 valid 24-hour urine collections is ≥ 0.70 mmol/24h/1.73m2. If taking pyridoxine (vitamin B6) for ...

5. Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA) - Mayo Clinic

   Absolute neutrophil count (ANC): ≥1500/µL ii. Platelets: ≥ 100 000/µL iii. Hemoglobin: ≥9.0 g/dL or ≥5.6 mmol/L. Criteria must be met without packed red ...

6. AZD5305 Vs Placebo In Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents - Mayo Clinic

   Serum potassium < 4.0 mmol/L. For combination with enzalutamide: History of seizure or any condition (as assessed by investigator) that may predispose to ...

7. 64Cu-SAR-bisPSMA And 67Cu-SAR-bisPSMA For Identification And Treatment Of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) - Mayo Clinic

   Hemoglobin ≥9 g/dL (5.59 mmol/L);. Total bilirubin ≤1.5 x the institutional upper limit of normal (ULN). For participants with known Gilbert's Syndrome ≤3 ...

8. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors - Mayo Clinic

   ... mmol/L) or hypertriglyceridemia (defined as fasting triglycerides > 2.5 x ULN), despite optimal medical therapy -; No known active hepatitis B (defined as ...

9. Glucagon (injection route) - Side effects & dosage - Mayo Clinic

   Glucagon injection is an emergency medicine used to treat severe hypoglycemia (low blood sugar) in diabetes patients treated with insulin who have passed out or ...

10. Myeloproliferative Disorders Clinical Trials - Mayo Clinic Research

    The purpose of this study is to collect and store tissue samples from patients who have myeloproliferative tumors, to be used to perform a variety of biomarker ...